Back to Browse Journals » Eye and Brain » Volume 3

Mitochondrial disorders and the eye

Authors Van Bergen NJ, Chakrabarti R, O’Neill EC, Crowston JG, Trounce IA

Published Date September 2011 Volume 2011:3 Pages 29—47

DOI http://dx.doi.org/10.2147/EB.S16192

Published 27 September 2011

Nicole J Van Bergen, Rahul Chakrabarti, Evelyn C O'Neill, Jonathan G Crowston, Ian A Trounce
Centre for Eye Research Australia, Department of Ophthalmology, University of Melbourne, Victoria, Australia

Abstract: The clinical significance of disturbed mitochondrial function in the eye has emerged since mitochondrial DNA (mtDNA) mutation was described in Leber's hereditary optic neuropathy. The spectrum of mitochondrial dysfunction has become apparent through increased understanding of the contribution of nuclear and somatic mtDNA mutations to mitochondrial dynamics and function. Common ophthalmic manifestations of mitochondrial dysfunction include optic atrophy, pigmentary retinopathy, and ophthalmoplegia. The majority of patients with ocular manifestations of mitochondrial disease also have variable central and peripheral nervous system involvement. Mitochondrial dysfunction has recently been associated with age-related retinal disease including macular degeneration and glaucoma. Therefore, therapeutic targets directed at promoting mitochondrial biogenesis and function offer a potential to both preserve retinal function and attenuate neurodegenerative processes.

Keywords: mitochondria, disease, retina, eye, aging, neuroprotection

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Relationship between interblink interval and dopamine

Lemon TI, Shah RD

Clinical Ophthalmology 2013, 7:793-794

Published Date: 29 April 2013

Update on neuromyelitis optica: natural history and management

Jindahra P, Plant GT

Eye and Brain 2012, 4:27-41

Published Date: 28 March 2012

Neuro-ophthalmic sarcoidosis

Baughman RP, Weiss KL, Golnik KC

Eye and Brain 2012, 4:13-25

Published Date: 14 March 2012

Multi-access drug delivery network and stability

Mitatha S, Moongfangklang N, Jalil MA, Suwanpayak N, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:1757-1764

Published Date: 23 August 2011

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011